PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

September 29, 2018

Primary Completion Date

December 10, 2019

Study Completion Date

January 10, 2020

Conditions
Cancer Pain
Interventions
DRUG

Hydromorphone

"1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."

DEVICE

PCA pump

"1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."

Trial Locations (1)

350014

Rongbo Lin, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT03375515 - PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain | Biotech Hunter | Biotech Hunter